Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,615 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, Jackson K, Kryzhanovskaya L, Jarkova N; HBBI Study Group. Kinon BJ, et al. Among authors: jackson k. J Clin Psychopharmacol. 2011 Jun;31(3):349-55. doi: 10.1097/JCP.0b013e318218dcd5. J Clin Psychopharmacol. 2011. PMID: 21508856 Clinical Trial.
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD. Patil ST, et al. Nat Med. 2007 Sep;13(9):1102-7. doi: 10.1038/nm1632. Epub 2007 Sep 2. Nat Med. 2007. PMID: 17767166 Clinical Trial.
Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid.
Lowe S, Dean R, Ackermann B, Jackson K, Natanegara F, Anderson S, Eckstein J, Yuen E, Ayan-Oshodi M, Ho M, McKinzie D, Perry K, Svensson K. Lowe S, et al. Among authors: jackson k. Psychopharmacology (Berl). 2012 Feb;219(4):959-70. doi: 10.1007/s00213-011-2427-9. Epub 2011 Aug 17. Psychopharmacology (Berl). 2012. PMID: 21847569 Clinical Trial.
Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects.
Mehta MA, Schmechtig A, Kotoula V, McColm J, Jackson K, Brittain C, Tauscher-Wisniewski S, Kinon BJ, Morrison PD, Pollak T, Mant T, Williams SCR, Schwarz AJ. Mehta MA, et al. Among authors: jackson k. Psychopharmacology (Berl). 2018 Jul;235(7):1875-1886. doi: 10.1007/s00213-018-4877-9. Epub 2018 Mar 21. Psychopharmacology (Berl). 2018. PMID: 29564482 Clinical Trial.
A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies.
Post A, Smart TS, Krikke-Workel J, Dawson GR, Harmer CJ, Browning M, Jackson K, Kakar R, Mohs R, Statnick M, Wafford K, McCarthy A, Barth V, Witkin JM. Post A, et al. Among authors: jackson k. Neuropsychopharmacology. 2016 Jun;41(7):1803-12. doi: 10.1038/npp.2015.348. Epub 2015 Nov 20. Neuropsychopharmacology. 2016. PMID: 26585287 Free PMC article. Clinical Trial.
Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis.
Chigutsa E, Velez de Mendizabal N, Chua L, Heathman M, Friedrich S, Jackson K, Reich K. Chigutsa E, et al. Among authors: jackson k. J Clin Pharmacol. 2018 Nov;58(11):1489-1500. doi: 10.1002/jcph.1268. Epub 2018 Jun 7. J Clin Pharmacol. 2018. PMID: 29878382 Clinical Trial.
2,615 results